☆ 4.7 Article Proceedings Paper

Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies

CANCER (2008)

期刊

CANCER

卷 112, 期 12, 页码 2710-2719

出版社

WILEY

DOI: 10.1002/cncr.23442

关键词

cetuximab; squamous cell carcinoma of the head and neck; head and neck cancer; cisplatin; carboplatin; second-line; epidermal growth factor receptor

类别

Oncology

向作者/读者索取更多资源

Protocol

社区支持

Reagent

社区支持

摘要

BACKGROUND. The epidermal growth factor receptor (EGFR) inhibitor cetuximab is active in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). The activity of cetuximab was compared with that of commonly used treatments in this setting. METHODS. All patients had recurrent and/or metastatic SCCHN and had progressed on cisplatin- or carboplatin-based chemotherapy. Efficacy data from 3 prospective studies (n = 278 patients) that administered cetuximab as a single agent (n = 103 patients) or combined with either cisplatin/carboplatin (n = 96 patients) or cisplatin (n = 79 patients) were compared with the results from a retrospective study of patients who received various second-line treatments (all treatments including best supportive care only, n = 151 patients; chemotherapy, n = 43 patients). Safety data considered were only those from the cetuximab studies. RESULTS. Over the 3 cetuximab trials, overall response rates from 10% to 13% and disease control rates from 46% to 56% were observed. The median time to disease progression ranged between 2.2 months and 2.8 months, and the median overall survival ranged between 5.2 months and 6.1 months. No patients who progressed on cetuximab alone responded to additional platinum. These survival data compared favorably with those from the retrospective study (median survival, 3.4 months [n = 151 patients] and 3.6 months [n = 43 patients]). Cetuximab-based treatments generally were tolerated well, and cetuximab did not increase the side effects associated with platinum therapy. CONCLUSIONS. Cetuximab has the potential to prolong survival in patients with recurrent and/or metastatic SCCHN who fail on platinum therapy compared with various second-line therapies. Cetuximab did not increase the toxicities associated with chemotherapy. The results obtained by treatment with cetuximab alone after platinum failure did not appear to differ from the results obtained by reintroducing platinum in combination with cetuximab.

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

主要评分

4.7

评分不足

次要评分

新颖性

重要性

科学严谨性

评价这篇论文

Weekly Paclitaxel, Carboplatin, and Cetuximab as First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma for Patients Ineligible to Cisplatin-Based Chemotherapy: A Retrospective Monocentric Study in 60 Patients

Helene Carinato, Mickael Burgy, Regine Ferry, Cathie Fischbach, Michal Kalish, Sebastien Guihard, Youssef Brahimi, Henri Flesch, Guy Bronner, Philippe Schultz, Veronique Frasie, Alicia Thiery, Martin Demarchi, Thierry Petit, Alain C. Jung, Pierre Wagner, Pierre Coliat, Christian Borel

Summary: The weekly PCC regimen appears to be a viable option for cisplatin-unfit patients, showing favorable PFS and OS compared to the EXTREME regimen. The study also demonstrates a high disease control rate and manageable toxicities in a more fragile patient population.

FRONTIERS IN ONCOLOGY (2021)